Patents by Inventor Manfred Konrad

Manfred Konrad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8349318
    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with altered or enhanced activity and broader substrate specificity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activities. Furthermore, the invention provides antibody-conjugated enzymes, pharmaceutical composition and kit containing the same, that can be specifically delivered to tumor cells.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: January 8, 2013
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Arnon Lavie, Manfred Konrad
  • Publication number: 20110129470
    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with altered or enhanced activity and broader substrate specificity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activities. Furthermore, the invention provides antibody-conjugated enzymes, pharmaceutical composition and kit containing the same, that can be specifically delivered to tumor cells.
    Type: Application
    Filed: May 18, 2009
    Publication date: June 2, 2011
    Applicant: The Board of Trustees of the University of Illnois
    Inventors: Arnon Lavie, Manfred Konrad
  • Patent number: 7858745
    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: December 28, 2010
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Arnon Lavie, Manfred Konrad, Farhad Ravandi
  • Patent number: 7419811
    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: September 2, 2008
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Arnon Lavie, Manfred Konrad, Farhad Ravandi
  • Publication number: 20070258968
    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
    Type: Application
    Filed: June 8, 2007
    Publication date: November 8, 2007
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Arnon Lavie, Manfred Konrad, Farhad Ravandi
  • Publication number: 20050008648
    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
    Type: Application
    Filed: March 1, 2004
    Publication date: January 13, 2005
    Inventors: Arnon Lavie, Manfred Konrad, Farhad Ravandi
  • Patent number: 6489443
    Abstract: A process for the preparation of a protein solution is described which is not prone to flock or particle formation even on heat treatment, the heat treatment being carried out in a glass vessel which has been rinsed out beforehand with a detergent solution and then with distilled water or another detergent-free solvent.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: December 3, 2002
    Assignee: Aventis Behring GmbH
    Inventors: Jürgen Römisch, Jörg Weisse, Jean Luc Veron, Juliana Djordjevich, Wilfried Freudenberg, Michel Grandgeorge, Barbara Kalina, Peter Kappus, Manfred Konrad, Gregory S. Rood, Werner Thill
  • Patent number: 4868521
    Abstract: A method and a circuit for exciting an ultrasonic generator comprises a control loop which includes the ultrasonic generator itself and a voltage-controlled oscillator. The control loop keeps the active power consumption to a desired value, which is compared in a comparator with the instantaneous active power consumption. One output of a further rectangular oscillator is connected to the control input of the voltage-controlled oscillator. The rectangular oscillator is put into operation if in the control loop there are no control oscillations or only those which are smaller than a predetermined threshold. The output of the rectangular oscillator is connected across one diode to the control input of the voltage-controlled oscillator and across another diode to the controlled input of comparator. The additional signal is applied to the voltage-controlled oscillator, apart from the control signal of the control loop.
    Type: Grant
    Filed: August 16, 1988
    Date of Patent: September 19, 1989
    Assignee: Satronic, AG
    Inventor: Manfred Konrad